Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Extensive Stage Small Cell Lung Cancer
NCT00887159Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib, cixutumumab in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started Jul 2009; status: completed.
02
Drugs
vismodegibcixutumumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00887159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887159.